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INTRODUCTION
Angiogenesis is the process of de novo formation of blood 
vessels in an organ or tissue. It has drawn much attention 
in recent years being one of the most studied scientific top-
ics worldwide. This is due to the fact that about 500 million 
people on the planet need a therapeutic correction of wide 
range of pathological processes associated with angiogenesis 
[1]. Angiogenesis involves the formation of new blood capil-
laries from pre-existing vessels, formed in an earlier stage of 
vasculogenesis, and the organization of these new capillar-
ies into the vascular network. The growth of the vasculature 
continues by continuous sprouting and splitting [2]. Under 
physiological conditions, angiogenesis plays essential role in 
the development and growth of tissue, wound healing, and 
menstrual cycle in women [3]. Pathological angiogenesis is 
a crucial incident in the transformation of benign tumors 
into malignant ones. It also plays a key role in tumor me-
tastasis, atherosclerosis, diabetic retinopathy, endometriosis, 
and proliferative skin diseases. In ischemic conditions such 
as myocardial infarction and cerebral stroke, the growth rate 
of new blood vessels is imperfect [4]. 
Vascular endothelial growth factor (VEGF) is an ex-
tremely specific mitogen for vascular epithelial cells and for 
micro- and macrovascular cells of lymph vessels. Its normal 
function is to stimulate both vasculogenesis (the de novo 
formation of the vascular system during embryonic devel-
opment) and angiogenesis (the growth of new blood vessels 
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from pre-existing vasculature) after tissue injury, muscular 
exercise, and to form new collateral circulation to bypass 
impeded vessels. It has a strong effect on permeability of 
blood vessels and is a powerful angiogenic protein in vari-
ous neovascularization processes in pathological conditions 
[5]. Recent research has shed light on VEGF as an important 
modulator of skin function in both health and disease [6-
7]. In many skin disorders such as atopic dermatitis, allergic 
contact dermatitis, psoriasis, phototoxicity and epidermal 
barrier dysfunction, dysregulated differentiation/prolifera-
tion and impaired intercellular communication in keratino-
cytes are observed [8]. Therefore, there have been exhaustive 
efforts to clarify the pathogenic role of VEGF in alteration of 
keratinocyte function and implication in skin diseases [9]. 
In this review we will discuss the implication of VEGF as 
a pathogenic biomarker in skin diseases by inspecting the 
available experimental and clinical evidences for the poten-
tial of VEGF in some dermatologic disorders.
THE FUNDAMENTAL CHARACTERISTICS 
OF VEGF
VEGF isoforms
In 1989, Ferrara and Henzel isolated a releasing endothelial 
cell-specific protein from cultured bovine pituitary follicu-
lar cells. They named it “vascular endothelial growth factor” 
to indicate the target cell specificity of this molecule [10-
11]. In 1997, Muller and co-workers [12] later obtained the 
crystal structure of VEGF at 1.93 Å resolution. Resolution 
of the crystal structure of VEGF has shown that VEGF is 
homodimeric glycoprotein that forms an antiparallel ho-
modimer linked covalently by two disulfide bridges (Fig 1). 
VEGF is produced by various types of cells and existing in 
at least 5 isoforms with parallel biological activity, but sig-
nificantly different in bioavailability. It is part of the system 
that restores tissue oxygenation in hypoxic conditions [13]. 
To date, the VEGF family includes 5 members, which are 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (placental 
growth factor). Fundamentally, all the VEGF members have 
8 conserved cysteine residues at constant positions, which 
are very similar to the PDGF family such as macrophage col-
ony stimulating factor (M-CSF) and stem cell factor (SCE) 
[14]. The best studied VEGF sub-family member is VEGF-A 
which can be determined in plasma and serum in detectable 
amounts. Due to alternative exon splicing, VEGF-A exists in 
at least 4 isoforms such as VEGF121, VEGF165, VEGF189, 
and VEGF206 corresponding to their primary amino acid 
structure [15], with the major isoform of all VEGF types 
being the VEGF165 variant of VEGF-A having a molecular 
weight of 45 kD and exerts the most potent biological activ-
ity [11]. VEGF-A is involved in many pathological processes 
associated with increased angiogenesis and/or vascular per-
meability. Examples where VEGF-A plays an important role 
are rheumatoid arthritis and inflammatory bowel disease 
[16]. Diabetic retinopathy is another condition associated 
with high intraocular levels of VEGF-A [17].
VEGF receptors
VEGF binds to type V tyrosine kinase family of receptors 
(RTK) with high affinity and selectivity, resulting in intra-
cellular signaling [18]. The VEGFRs are characterized by 
having extracellular part consisting of 7 domains resem-
bling that of the human immunoglobulin molecules, a single 
transmembrane spanning region, and an intracellular part 
containing a split tyrosine-kinase component [18]. They are 
predominantly expressed on endothelial, hematopoietic, and 
connective tissue cells [19]. To date, 3 subtypes of VEGFRs 
are defined, which are VEGFR-1, VEGFR-2, and VEGFR-3 
[18]. Different VEGF sub-family members interact with 
these receptors with variable affinity and selectivity (Fig 2). 
Fig 1. A top-down view of the VEGF dimeric protein molecule 
as represented in ribbon model. The two VEGF monomers 
are shown in blue and red. The termini of both monomers 
are labeled. (Adapted from: Muller YA, De Vos AM. Vascular 
endothelial growth factor refined to 1.93 angstroms resolution. 
PDB ID 2VPF, DOI: 10.2210/pdb2VPF/pdb).
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Studies have also shown that the neuropilin receptors (NRP-
1 and 2) can act also as co-receptors to enhance VEGF sig-
naling by modulating the VEGF-VEGFR interaction [20]. 
The general mechanistic pathway of VEGFR signaling is 
analogous to typical RTK signaling of known growth factors, 
such as PDGF, in regulating cell differentiation, prolifera-
tion and migration [21]. VEGFR-1 is thought to play critical 
roles in the development of embryonic vascular system (vas-
culogenesis) as a result of its activation by VEGF-A and B. 
VEGFR-2 is thought to be responsible for mediating a wide 
array of angiogenic actions such as endothelial proliferation, 
migration, and microvascular permeability by binding with 
VEGF-A. VEGFR-3 is predominantly located in lymphatic 
vascular tree, and promotes lymphangiogenesis by binding 
with VEGF-C and D [19, 22].
Role of VEGF in angiogenesis
The main mechanism regulating the process of angiogenesis 
is the release of angiogenic factors which activate receptors 
on endothelial cells present in pre-existing blood vessels. 
The activated endothelial cells start releasing proteolytic en-
zymes that degrade the basement membrane to allow endo-
thelial proliferation and migration into the adjacent matrix 
to form new sprouts connecting the neighboring vessels. The 
new vascular growth is determined by the balance between 
stimulating and inhibiting factors (Table 1). With a low ratio 
of stimulants to inhibitors of vascular formation, angiogen-
esis is halted or proceeds in slow rate, but at high ratios, an-
giogenesis is actively triggered [23].
Normally, VEGF is found in tissues in detectable amount. 
Cells that express this cytokine include macrophages, fibro-
blasts, lymphocytes, polymorphonuclear leukocytes, osteo-
blasts, endothelial and smooth muscle cells, mesangial cells 
of the kidneys, platelets, and keratinocytes [24]. On the other 
hand, these cells express VEGFRs to recognize and respond 
to VEGF in a mutual way. The transcription of VEGF mRNA 
is induced by various growth factors and cytokines including 
PDGF, EGF, tumor necrosis factor (TNF)-α, TGF-β, IL-1β, 
Fig 2. Actions of different VEGF isoforms on the 3 major types of VEGFRs. VEGF-A and B activate VEGFR-1 to 
promote embryonic vasculogenesis. VEGF-A acts on VEGFR-2 to promote angiogensis in many physiological and 
pathological conditions. VEGF-C and D act on VEGFR-3 in the lymphatic vasculature to promote lymphangiogenesis. 
The NRP (neuropilin) receptors act as co-receptors to enhance VEGFRs signaling.
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and IGF-II [25]. VEGF level in human serum progressively 
decreases after birth and remains low in most adult tissues 
beyond sites of active angiogenesis, such as ovaries, uterus, 
skin and its appendages [26]. However, VEGF expression is 
re-induced at times of pathological angiogenesis. In patients 
with tumors, VEGF can cause significant changes in hemo- 
and lymphopoiesis at the level of bone marrow and thymus. 
It is believed that the increased levels of this factor creates the 
basis for development of immunodeficiency and helps the 
tumor escape from immune surveillance [27]. Addition of 
VEGF to rat T lymphocytes that are stimulated by a mitogen 
or antigen caused an increase in interferon (INF)-γ produc-
tion and a decrease in IL-10 [28].
Given that VEGF is stress-induced protein, its regulation 
is influenced by tissue oxygen status; therefore, physiolog-
ical and pathological angiogenesis can be considered as a 
regulatory response to oxygen deficiency [29]. There is an 
activation of metabolic pathways regulated by proteins such 
as hypoxia-induced factor 1 (HIF-1), which leads to an in-
crease in the expression of pro-angiogenic factors, includ-
ing VEGF and fibroblast growth factor (FGF) [30]. At the 
moment when the action of pro-angiogenic factors exceeds 
the effect of anti-angiogenic factors, endothelial cells pass 
from the usual dormant state to the active one. Following 
turning on angiogenesis, degradation of vascular basement 
membranes and liquefaction of the extracellular matrix by 
increased activity of matrix metalloproteinase (MMP) facil-
itate the migration of endothelial cells into the extravascular 
space, where they begin to multiply and organize to form 
new capillary network. During this process, pericytes are at-
tracted to the newly formed vessels and stabilize them [2-4]. 
In this way, VEGF functions in dynamic orchestration with 
cytokines, their soluble receptors and inhibitors, and pro-
teolytic enzymes to regulate endothelial cell migration and 
proliferation during angiogenisis.
The importance of VEGF-A for tumor growth was clearly 
demonstrated by using VEGFR-2 antagonists to block tumor 
cell proliferation [31]. As a result, interfering with VEGF-A 
function has become a major interest for the development of 
drugs aimed at blocking angiogenesis and metastasis. Cur-
rently, more than 110 pharmaceutical companies worldwide 
are developing such antagonists. Their approaches include 
antibodies against VEGF-A or antagonists to VEGFR-2 [32]. 
In general, the targeting of VEGF signaling can be of great 
therapeutic value for many diseases and serve as the basis for 
the development of future antiangiogenic therapies.
VEGF EXPRESSION AND SIGNALING 
PATHWAYS IN KERATINOCYTES
The expression of VEGF in keratinocytes of rodent skin 
during wound repair was first observed by Brown and 
co-workers in 1992 [33]. Following this observation, the 
cellular source of cutaneous VEGF was extensively investi-
gated. Both epidermal keratinocytes and dermal fibroblasts 
are capable of expression of VEGF, but interestingly, kerati-
nocytes were shown to be the principal source of cutaneous 
VEGF. In cultured human keratinocytes, significant expres-
sion of VEGF was observed after stimulation with serum, 
EGF, TGF-β1, TNF-α, or IGF [34-35]. It was recently found 
that epidermal keratinocytes and dermal fibroblasts were 
able to express the three main VEGF isoforms (VEGF121, 
VEGF165, and VEGF189) in co-culture. Moreover, these 
Table 1. Stimulators and inhibitors of angiogenesis
Angiogenic stimulators Angiogenic inhibitors
Vascular endothelial growth factor (VEGF)
Fibroblast growth factor (FGF)
Epidermal growth factor (EGF)
Platelet-derived growth factor (PDGF)
Transforming growth factor-beta (TGF-β) 
Insulin-like growth factors I and II (IGF-I &II)
Interleukin (IL)-1α & IL-8
Non-specific factors such as matrix 
metalloproteinase (MMP)
Endostatin
Soluble VEGF receptors (sVEGF-R)
Thrombospondin
Angiostatin (plasminogen fragment)
Vasostatin
MMP inhibitors
Delta-like ligand 4 (DII4)
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factors were expressed in much higher levels in epidermal 
keratinocytes than dermal fibroblasts [7]. Cutaneous VEGF 
serves as a potent and specific mitogen for dermal microvas-
cular endothelial cells and a crucial mediator for increased 
angiogenesis and vascular permeability during the process 
of wound repair [36] and hair growth [37]. It has also main 
contribution in many cutaneous pathological conditions in-
cluding cutaneous inflammation [38], skin cancer [39] and 
psoriasis [40]. 
Various growth factors and cytokines are known to 
up-regulate VEGF expression in epidermal keratinocytes, 
including ILs, TGF-α and β, TNF-α, EGF, and PDGF [base, 
nm]. Contribution of intracellular signaling kinases, includ-
ing phosphatidylinositol 3-kinase (PI3K) and mitogen-acti-
vated protein kinase (MAPK) to VEGF synthesis in kerati-
nocytes are also well-documented [41-42]. Transcriptional 
regulation of VEGF in keratinocytes is also shown to be me-
diated by transcription factors such as activation protein 
(AP)-1 and 2, HIF, and nuclear factor kappa-B (NFkB) [43-
45]. Additionally, skin exposure to ultraviolet irradiation 
promotes up-regulation of VEGF expression in keratino-
cytes either by direct induction of transcriptional pathways 
or by release of soluble cytokines [46-47].
PATHOLOGICAL ROLE OF VEGF IN SKIN 
DISEASES
The cellular and molecular mechanisms underlying physi-
ological and pathological angiogenesis are now being ex-
tensively studied in the field of dermatology. Recent studies 
show that VEGF plays key roles in wound healing, psoriasis, 
contact dermatitis, lichen planus, alopecia, and skin carcino-
genesis. Although it is now established that VEGF is signifi-
cantly expressed in keratinocytes and dermal fibroblasts, it is 
still debated whether cutaneous VEGF is restorative or exac-
erbative for abnormal skin conditions.
Psoriasis
Studying the mechanisms of formation of psoriatic plaque, 
the main morphological feature of the disease, showed the 
role of dermal vascular changes [48]. They appear earlier 
than epidermal changes and persist for a longer time after 
treatment. Moreover, dermal vascular changes are detected 
in the clinically healthy skin of patients and their first degree 
[49]. During recovery, only epidermal disorders are normal-
ized while the inflammatory process persists in the dermis, 
especially in blood vessels. In situ hybridization and immu-
nohistochmistry of skin biopsies from psoriatic patients 
show marked up-regulation of VEGF mRNA and protein 
expression in keratinocytes [50] and increased expression of 
VEGFR-1 and -2 on endothelial cells of the dermal papillae 
[51]. It was shown that serum levels of VEGF and the solu-
ble form of VEGFR-1 in patients with conventional psoriasis 
significantly exceeded the values in the control group and 
correlated significantly with the Psoriasis Area and Sever-
ity Index (PASI) [52]. Additionally, a close correlation was 
found between the initial values of the PASI index and the 
concentration of VEGF in the blood serum of patients with 
exudative psoriasis [40]. Overexpression of VEGF in skin 
lesions of psoriatic patients showed also a positive correla-
tion with TNFα, MMP-2, and HIF [40]. In the early stages of 
psoriatic arthritis, the content of VEGF and TGF-β in the sy-
novial fluid is also increased [40]. Studies have documented 
the possibility of induction of psoriasis under the influence 
of VEGF and both IGF-I and II, which are powerful auto-
crine-paracrine regulators of cell growth and differentiation 
[53].
Recent studies on the dynamics of the progression of 
the psoriatic process have shown that one of the key factors 
determining the pathogenesis of this disease is dysregulated 
angiogenesis [54]. VEGF is recognized as a crucial pro-an-
giogenic mediator responsible for the de novo formation of 
blood vessels in psoriatic plaques [40]. The involvement of 
angiogenesis in the development of psoriasis has been prov-
en with the discovery of gene polymorphism in relation to 
VEGF. In patients with severe psoriasis, a systemic dysregu-
lation of VEGF was observed due to polymorphic variants of 
VEGF receptors in activated keratinocytes [55]. Assessment 
of the state of angiogenesis in children suffering from psori-
asis revealed a significant increase in the expression level of 
VEGF and IGF-I; however, the increase in IGF-II in all age 
groups was not confirmed [56]. 
Additional evidence of the pathogenic role of VEGF in 
psoriasis is provided by the effect of therapy. Treatment of 
psoriasis with topical steroids leads to significant decrease 
in the concentration of serum VEGF, especially in patients 
with severe disease (PASI> 20), and an increase in the con-
centration of soluble VEGFR-1 in patients with mild dis-
ease activity (PASI <10) [57]. Moreover, the serum levels of 
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VEGF and MMP-9 in patients with psoriasis vulgaris de-
creased after 4 weeks of treatment with the cytostatic drugs, 
methotrexate [58] while therapy of patients with psoriasis 
according to the Goeckerman method reduced the levels of 
VEGF and FGF that were significantly high before treatment 
[59]. Studies have also shown that infliximab has a positive 
effect by suppressing the VEGF/angiopoietin/Tie-2 signal-
ing pathway [60]. Another evidence of the importance of 
anti-angiogenic therapy for psoriasis is obtained by studying 
retinoids that become biologically active as a result of their 
interaction through one of two ways: interaction with their 
nuclear receptors (retinoic acid receptors) or with the nu-
clear transcription factor AP-1. There are four AP-1 binding 
sites in the promoter region of the VEGF gene; the interac-
tion of retinoids with AP-1 blocks the expression of VEGF, 
therefore, retinoids have anti-VEGF activity [61]. Taken col-
lectively, targeting VEGF and/or VEGFRs has been recently 
proposed as a new treatment for psoriasis [62-63], since the 
use of anti-VEGF antibodies in mouse models of psoriasis 
has shown relief of the symptoms of the disease [64].
Lichen planus
Despite several studies, the exact pathogenesis of lichen pla-
nus has not been fully understood [65]. Data in the literature 
point at involvement of angiogenic process and hypoxia, as 
well as involvement of inflammatory cells secreting media-
tors such as TNFα, IL-1, and IGF leading to the induction 
of VEGF [30, 35, 38]. In such angiogenic dermatoses, over-
expression of VEGF mRNA was clearly defined in the upper 
part of the prickly and granular layers and correlates with the 
density of microvessels in the papillary dermis [66]. Accord-
ing to the authors, therapy aimed at normalizing the level of 
VEGF may lead to persistent remission of the disease, espe-
cially when the mucous membrane is involved such as oral 
lichen planus (OLP). 
In a study published in 2007, Tao and colleagues investi-
gated the microvascular density and expression of VEGF in 
patients with OLP, and found that angiogenesis and VEGF 
expression were closely correlated to the severity of OLP 
lesions [67]. Similar results were obtained by Scardina and 
co-workers who reported that 64.2% of OLP samples show 
significant VEGF expression and considerable neoangiogen-
esis [68]. Likewise, the serum VEGF level was significantly 
higher in patients with oral lichen planus compared with the 
healthy controls [69]. Rhodus and co-workers showed that 
a panel of pro-angiogenic cytokines, including TNF-α, IL-1, 
IL-6, and IL-8 are markedly elevated in samples of tissues 
and oral fluids in patients with OLP [70]. These cytokines 
can, indeed, lead to overexpression of VEGF and increased 
VEGF in serum. Taking into consideration the angiogenic 
abnormalities and the overexpression of angiogenic factors 
in lichen planus, as occurs in many other inflammatory con-
ditions [71], new therapeutic strategies based on the use of 
anti-angiogenic medicine could be promising. These medi-
cations are already in use for other conditions with chronic 
inflammatory pathologies and are exhibiting good results 
[72].
Inflammatory skin diseases
Some of the pathological characteristics of inflammation 
include the infiltration of tissue with acute and chronic in-
flammatory cells, release of inflammatory mediators and 
increased vascular permeability. Vascular remodeling is a 
characteristic feature of chronic inflammatory skin diseas-
es in which angiogenesis and inflammation are closely con-
comitant [72-73]. Atopic dermatitis is a common, chronic 
inflammatory skin disease in which, beside immune dys-
regulation, angiogenesis also plays a key role [74]. Samples 
from plasma and skin of patients with atopic dermatitis show 
increased levels of VEGF when compared with control sam-
ples [75]. Moreover, the association between polymorphisms 
of the VEGF/VEGFR genes and atopic dermatitis has been 
confirmed [76]. Chronic urticaria is another inflammatory 
condition in which the association with angioedema is pres-
ent in approximately 40% of patients [77]. Release of hista-
mine and other vasoactive mediators from dermal mast cells 
causes characteristic skin wheals that are red, raised, and 
itchy [76]. It has been suggested that VEGF plays a critical 
role in the increased vascular permeability, edema, and in-
flammatory cell infiltrates pathognomonic for chronic urti-
caria [78]. Studies have confirmed the increase of VEGF in 
plasma and skin samples of patients with chronic urticar-
ia, and these levels are correlated with disease severity [79]. 
Several cellular types, including mast cells, eosinophils, and 
basophils contribute to increased levels of VEGF in plasma 
and skin [79]. Therefore, infiltrating inflammatory cells can 
play important role in whealing of the skin and tissue ede-
ma characteristic of chronic urticaria through the release of 
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VEGF [78].
Phototoxicity
Phototoxicity is a broad term that includes all forms of skin 
damage induced by ultraviolet (UV) irradiation such as 
photo-irritation, photo-sensitization, photo-aging, and pho-
to-carcinogenesis. UV irradiation causes generation of reac-
tive oxygen species (ROS) that can induce damage to DNA 
and cellular macromolecules [80]. UV exposure provokes 
skin irritation, hyperaemia, hyper-permeability, edema, and 
angiogenesis, which are closely connected with VEGF. Sever-
al studies have shown that UV exposure induces overexpres-
sion of VEGF in keratinocytes either directly by activating 
nuclear transcription factors such as NFκB, AP-1 and AP-
2, or indirectly by releasing soluble cytokines such as IL-1 
and TNF-α [81-83]. While UVB induced VEGF overexpres-
sion in primary human keratinocytes and in premalignant 
keratinocytes cell line (HaCaT) [82], UVA induced VEGF 
overexpression only in premalignant keratinocytes cell line 
[84] suggesting significant contribution of cutaneous VEGF 
signaling in the premalignant keratinocytes which may pro-
mote carcinogenic transformation.
Hair growth and alopecia
Impairment of the vascularization of hair follicles plays crit-
ical role in the pathogenesis of conditions characterized by 
increased hair loss [85]. Human hair follicles are constantly 
involved in a cyclic change of growth and regression, which 
requires appropriate changes in skin vascularization during 
the life cycle. In the anagen phase, the requirements of hair 
follicles for energy substrates are significantly increased, 
therefore, the size of the perifollicular vessels increases, 
while in the catagen and telogen phases, the size of vessels 
decreases [85]. VEGF is one of the principal mediators of 
hair follicle survival, having a direct effect on their vascu-
larization, as well as various cellular functions, including 
cell lifespan, proliferation, and the formation of nitric oxide 
and prostacyclin [37]. In vivo VEGF increases microvascular 
permeability and angiogenesis, promotes mutual adhesion 
of keratinocytes of the hair, increases the strength, thickness 
and density of the hair [37, 85]. In dermal papillae of hair fol-
licles, VEGF stimulates the proliferation of matrix and vas-
cular endothelial cells, and synthesis of extracellular matrix 
material, thus maintaining the follicles in the anagen state 
[86]. In addition, VEGF enhances the production of nitric 
oxide by eNOS synthase and increasing cell permeability for 
the movement of nutrients [87]. In experimental studies on 
transgenic mice with increased expression of VEGF in kerat-
inocytes, the cells of the dermal papillae displayed enhanced 
perifollicular vascularization, accelerated hair restoration 
after depilation, and growth of longer hair [37]. Conversely, 
VEGF blockade by the systematic administration of neutral-
izing VEGF antibodies slows down hair growth and reduces 
the size of hair follicles [37]. 
For long time, the endogenous androgen dihydrotestos-
terone (DHT) has been considered responsible for hair loss 
during androgenetic alopecia [88]. This hormone binds to 
follicle receptors and inhibits Bcl-2, which leads to cell apop-
tosis. It has been shown that VEGF plays a critical role in 
the prevention of premature apoptosis of hair follicle cells, 
contributing to the suppression of caspase 9 genes and the 
interaction of Bcl-2 with the Bax and Bad genes, and also 
provides protection against hypoxia and oxidative stress; 
therefore, the anagen phase lasts for longer time [37].  Given 
the pivotal role of VEGF in hair biology, this growth factor 
can be an effective method in the treatment of conditions 
characterized by impaired hair growth and miniaturization 
of hair follicles. Studies have shown that the effectiveness of 
minoxidil in treatment of hair loss is attributed, at least par-
tially, to its promoting effect on VEGF synthesis and release 
[89]. It was found that minoxidil activates the expression of 
VEGF in the cells of the dermal papillae in the anagen phase 
ensuring sufficient follicular vascularization [90]. In the cells 
of skin papillae isolated from the hair follicle of the scalp, the 
addition of minoxidil led to increased expression of VEGF 
mRNA. 
Diphenylcyclopropenone (diphencyprone) is a topically 
administered experimental drug intended for treating alo-
pecia areata and alopecia totalis [91]. Recent studies have 
shown that this drug normalizes the ratio of CD4/CD8 cells 
in the skin that were dysregulated in patients with alopecia 
areata, and upregulates the expression of survivin, thus pre-
vents premature apoptosis [92]. Diphencyprone also induces 
the expression of VEGF in keratinocytes of the hair follicles, 
providing good of nutrients and oxygen [93].  In summary, 
it is well known that minoxidil and anti-DHT drugs are ef-
fective against androgenetic alopecia, and diphencyprone is 
a promising treatment for alopecia areata. Treatments based 
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on VEGF enhancing may provide  alternative to these treat-
ments, or boost the effect of all the already present therapeu-
tic options.
Conclusion
The present article reviewed the role of VEGF in the patho-
genesis of skin diseases. From the data presented in this arti-
cle, it is clear that studies of the angiogenesis and pathogenic 
role of VEGF in skin diseases are beginning to be intensively 
organized. This will pave the road to develop new therapeu-
tic strategies based on molecular understanding of disease 
pathogenetic processes and signaling proteins interaction in 
various skin diseases.
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